Loading
collectionsCollection
CSCO guidelines (China)
CSCO guidelines are China's national oncology guidelines, covering about 30 cancers and updated annually. They grade each recommendation by both evidence level and affordability under China's reimbursement list, and they cover Chinese-developed drugs (PD-1 inhibitors, ADCs) and cancers common in China (nasopharyngeal, oesophageal, liver, gastric) years before Western guidelines.
Overview
CSCO guidelines (since 2016 in current form) use a two-dimensional system: evidence level (1A-3) and recommendation grade (I basic, II optional, III) that considers drug accessibility, cost and reimbursement in China's National Reimbursement Drug List. They cover Chinese approvals (toripalimab, camrelizumab, sintilimab, tislelizumab, disitamab vedotin, furmonertinib, savolitinib) years before Western uptake and are published in English for several tumours (e.g. joint CSCO/ASCO NPC guideline 2021). Read with the NMPA approvals list for a view of the world's second-largest oncology market.
Holds
Chinese Society of Clinical Oncology guidelines for ~30 cancers, graded by evidence and by accessibility/affordability in China (basic vs optional strategies), updated annually.
Licence
CSCO
Maintainer
Chinese Society of Clinical Oncology
Similar pages
- CollectionASCO clinical practice guidelines
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS and the tag guidelines.
- CollectionNICE cancer guidance and technology appraisals (UK)
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag guidelines.
- CollectionJapanese oncology guidelines (JSMO, JSCO and organ societies)
Shares Oesophageal cancer, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer and the tag guidelines.
- PersonFlorian Lordick
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag guidelines.
- PersonRui-Hua Xu
Shares Chinese Society of Clinical Oncology, Sun Yat-sen University Cancer Center, Camrelizumab, Toripalimab.
- PersonEric Van Cutsem
Shares Gastric & gastro-oesophageal junction cancer and the tag guidelines.
- PersonJun Guo
Shares Chinese Society of Clinical Oncology, Peking University Cancer Hospital, Toripalimab.
- PersonJing Huang
Shares Cancer Hospital, Chinese Academy of Medical Sciences, Camrelizumab, Oesophageal cancer.
cancers
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Camrelizumab · AiRuiKa
ApprovedAnti-PD-1 monoclonal antibody (IgG1, Fc-engineered null)
Penpulimab · Penpulimab-kcqx
ApprovedMonoclonal antibody (anti-PD-1)
Tislelizumab · Tevimbra
ApprovedMonoclonal antibody (anti-PD-1)
Toripalimab · Loqtorzi